TRIAL DATE SET FOR SEROQUEL® PATENT LITIGATION AstraZeneca today announced a trial date has been set for patent litigation in the US District Court for the District of New Jersey against Teva Pharmaceutical Industries Ltd. and Sandoz, Inc. alleging infringement of AstraZeneca's patent as a result of Teva's and Sandoz's filings of Abbreviated New Drug Applications (ANDAs). The ANDAs seek approval to market generic versions of SEROQUEL® (quetiapine fumarate tablets) in the US before SEROQUEL's patent expires in 2011. The Court has set a date for trial beginning on 11 August 2008. For more information about AstraZeneca please visit: www.astrazeneca.com For further information: Media Enquiries: Neil McCrae, +44 207 304 5045 (24 hours) Steve Brown, +44 207 304 5033 (24 hours) Chris Sampson, +44 207 304 5130 (24 hours) Investor Enquiries: Jonathan Hunt, +44 207 304 5087 Ed Seage, +1 302 886 4065 Karl Hard, +44 207 304 5322 Jorgen Winroth, +1 212 579 0506 Mina Blair, +44 20 7304 5084 Peter Vozzo, (MedImmune) +1 301 398 4358
TRIAL DATE SET FOR SEROQUEL® PATENT LITIGATION
| Source: AstraZeneca PLC